WCM
FOLD

Wedge Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Wedge Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-129,224
Closed -$1.84M – 540
2025
Q4 		$1.84M Sell
129,224
-4,252
-3% -$41.8K 0.03% 357
2025
Q3 		$1.05M Sell
133,476
-11,234
-8% -$80K 0.02% 425
2025
Q2 		$829K Buy
144,710
+932
+0.6% +$6.01K 0.01% 448
2025
Q1 		$1.17M Sell
143,778
-45,007
-24% -$416K 0.02% 401
2024
Q4 		$1.78M Hold
188,785
– – 0.03% 345
2024
Q3 		$2.02M Sell
188,785
-44,264
-19% -$482K 0.03% 326
2024
Q2 		$2.31M Buy
233,049
+25,564
+12% +$262K 0.04% 297
2024
Q1 		$2.44M Sell
207,485
-16,433
-7% -$210K 0.04% 301
2023
Q4 		$3.18M Sell
223,918
-967
-0.4% -$11K 0.06% 275
2023
Q3 		$2.73M Buy
224,885
+30,990
+16% +$400K 0.05% 283
2023
Q2 		$2.44M Sell
193,895
-23,559
-11% -$280K 0.04% 351
2023
Q1 		$2.41M Sell
217,454
-11,426
-5% -$141K 0.04% 289
2022
Q4 		$2.79M Buy
+228,880
New +$2.58M 0.05% 287

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wedge Capital Management's FOLD Position: Q1 2026 in Review

Wedge Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 129,224 shares — an estimated $1.84M sold.

Wedge Capital Management first reported a position in FOLD in Q4 2022 and held it in 13 quarters. The position peaked at $3.18M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Wedge Capital Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wedge Capital Management sold 129,224 Amicus Therapeutics shares in Q1 2026, an estimated $1.84M.
  • Wedge Capital Management first reported a position in Amicus Therapeutics in Q4 2022 and held it in 13 quarters.
  • Wedge Capital Management's Amicus Therapeutics position peaked at $3.18M in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Wedge Capital Management's 13F filing for Q1 2026, filed 13 Apr 2026.